Company intelligence / Profile preview

Genvax

Ames, Iowa, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Genvax Technologies is a clinical-stage animal health company focused on developing next-generation vaccines using a proprietary mRNA-based platform. The company's technology allows for the rapid development of strain-specific vaccines that can be deployed quickly in response to emerging animal diseases. By utilizing a synthetic approach, Genvax aims to provide more effective and scalable solutions for livestock producers compared to traditional vaccine methods. Their lead programs target high-impact agricultural threats such as African Swine Fever and Swine Influenza.

Therapeutic areas: Infectious Diseases
Modalities: VaccinemRNA-based drugsDNA vaccineNanoparticle
Industry: Veterinary

Partnerships

United States Department of Agriculture (USDA)Iowa State University

Beyond the preview

Go deeper on Genvax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genvax.

Explore the full profile